(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Figure out How to Use the Experience of a Fender bender Legal counselor for Your Potential benefit - 2Exploring the School Application Cycle: Understudy Bits of knowledge
- 3Motivational Travel Objections for History Buffs
- 4The Specialty of Cleaning up: Change Your Space and Brain
- 5Top 20 Compelling Business Books for Progress
- Gym tied to outbreak of obscure disease that spreads through mist
- Extraordinary Shows to Long distance race on a Plane
- Experts who once backed 'shaken baby' science now fight to free imprisoned caregivers
- Viable Tips for Seniors to Purchase a Minimal expense Jeep Wrangler
- New law puts familiar drinks, creams and gummies in legal limbo
- 7 Well known Vacation spots In The US
- Electric discovery on Mars! Scientists find tiny lightning bolts coming from Red Planet dust clouds
- Well known Travel Booking Locales: What's Your Pick?
- Washington resident contracts bird flu, first human case in U.S. since February
